PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15963975-3	2005	Coadministration of icatibant, a bradykinin B(2)-receptor antagonist (200 microg/kg/day), with enalapril blunted the stimulatory effect of the ACE inhibitor on eNOS mRNA expression, circulating levels of nitrite/nitrate, the relaxant activity of ACh and the release of 6-keto-PGF1alpha in L-NAME-treated rats.	Enalapril	95-104	nitric oxide synthase 3	Rattus norvegicus	160-164	
31817916-7	2019	The thickness of the aortic wall did not differ between groups but the expression of endothelial nitric oxide synthase (eNOS) was increased in ethyl rosmarinate- and enalapril-treated groups compared with the hypertensive group.	Enalapril	166-175	nitric oxide synthase 3	Rattus norvegicus	85-118	
31817916-7	2019	The thickness of the aortic wall did not differ between groups but the expression of endothelial nitric oxide synthase (eNOS) was increased in ethyl rosmarinate- and enalapril-treated groups compared with the hypertensive group.	Enalapril	166-175	nitric oxide synthase 3	Rattus norvegicus	120-124	
31817916-8	2019	Conclusions: Ethyl rosmarinate is an interesting candidate as an alternative treatment for hypertension due to its ability to improve vascular function and to increase the expression of eNOS similar to enalapril which is a drug commonly used in hypertension.	Enalapril	202-211	nitric oxide synthase 3	Rattus norvegicus	186-190	
12176110-0	2002	Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats.	Enalapril	0-9	nitric oxide synthase 3	Rattus norvegicus	76-80	
14563973-1	2003	BACKGROUND AND PURPOSE: Our goal was to identify the effects of chronic treatment with enalapril on cerebrovascular dysfunction and endothelial nitric oxide synthase (eNOS) protein in diabetic rats.	Enalapril	87-96	nitric oxide synthase 3	Rattus norvegicus	132-165	
12176110-4	2002	In L-NAME-treated rats, administration in the last 2 weeks of either the angiotensin-converting enzyme inhibitor enalapril (1 mg/kg/day) or the cognate drug quinapril (1 mg/kg/day) decreased systolic blood pressure levels, completely restored eNOS mRNA levels in aortic tissue, and allowed a consistent recovery of both the relaxant activity of ACh and the generation of 6-keto-PGF(1 alpha).	Enalapril	113-122	nitric oxide synthase 3	Rattus norvegicus	243-247	
12176110-7	2002	Angiotensin-converting enzyme inhibition by enalapril or quinapril was equally effective in improving endothelial vasodilator function, prostacyclin endothelial production and restoring aortic eNOS mRNA.	Enalapril	44-53	nitric oxide synthase 3	Rattus norvegicus	193-197